United States Biotechnology & Medical Research

Evommune Inc (EVMN)

Track

Track

Evommune Inc. experienced significant selling pressure recently, with insiders offloading over $5 million in shares. Despite this, two individuals purchased stock totaling $146,260. These transactions occurred amid a 40% decline in equity value over three months and a disappointing earnings report, reflecting a challenging period for the healthcare firm.
Ticker: EVMN Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Evommune Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Carver Kyle Chief Financial Officer Officer
Transaction date
Purchase
Price
90.36
Quantity 13,679 -45.2%
Value US$2,824,750
3.1
KIRSCH ARTHUR S Non-Executive Director
Transaction date
Purchase
Price
278.21
Quantity 62,535 +48.6%
Value US$1,869,261
Drew Janice Suzann Chief of Dev. Operations Officer
Transaction date
Planned sale
Price
373.64
Quantity 46,072 +31.1%
Value US$4,467,497
Pena Luis C. President & CEO Executive Director
Transaction date
Planned sale
Price
22.71
Quantity 7,438 -1.2%
Value US$168,917
Patel Jeegar Pravinkumar Chief Scientific Officer Officer
Transaction date
Planned sale
Price
22.50
Quantity 1,488 -3.1%
Value US$33,480
JANICE DREW Officer Officer
Transaction date
Proposed sale
Price
21.36
Quantity 20,000
Value US$427,200
JANICE DREW Officer Officer
Transaction date
Proposed sale
Price
21.36
Quantity 20,000
Value US$427,200
Cohen David E Non-Executive Director
Transaction date
Planned sale
Price
21.38
Quantity 600 -3.3%
Value US$12,828
Cohen David E Non-Executive Director
Transaction date
Planned sale
Price
20.21
Quantity 5,456 -23.1%
Value US$110,266
DAVID COHEN Director Non-Executive Director
Transaction date
Proposed sale
Price
22.17
Quantity 9,258
Value US$205,250
Patel Jeegar Pravinkumar Chief Scientific Officer Officer
Transaction date
Planned sale
Price
22.74
Quantity 16,687 -26.4%
Value US$379,462
Pena Luis C. President & CEO Executive Director
Transaction date
Planned sale
Price
22.74
Quantity 16,787 -2.6%
Value US$381,736
LUIS PENA Director; Officer Executive Director
Transaction date
Proposed sale
Price
23.23
Quantity 24,225
Value US$562,747
JEEGAR PATEL Officer Officer
Transaction date
Proposed sale
Price
23.23
Quantity 18,175
Value US$422,205
Moss Gregory S. Chief Business & Legal Officer Officer
Transaction date
Planned sale
Price
22.83
Quantity 14,223 -18.9%
Value US$324,711
Carver Kyle Chief Financial Officer Officer
Transaction date
Planned sale
Price
22.84
Quantity 18,175 -23.4%
Value US$415,117
KYLE CARVER Officer Officer
Transaction date
Proposed sale
Price
23.34
Quantity 25,675
Value US$599,254
GREGORY MOSS Officer Officer
Transaction date
Proposed sale
Price
23.34
Quantity 14,223
Value US$331,965
2.5
Hopfner Robert Lorne Non-Executive Director Large shareholder
Transaction date
Purchase
Price
17.35
Quantity 1,000 +33.0%
Value US$17,350
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
16.00
Quantity 92,904 +13.4%
Value US$1,486,464
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
16.00
Quantity 1,157,096 +76.3%
Value US$18,513,536
LSP 7 Cooperative UA Large shareholder
Transaction date
Purchase
Price
16.00
Quantity 1,562,500 +46.4%
Value US$25,000,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-10 2026-07-08 B Purchase
Carver Kyle

Chief Financial Officer

Officer
13,679 -45.2%
90.36
US$2,824,750 		13,679 -45.2% 90.36 US$2,824,750
2026-07-08 2026-07-07 B Purchase
3.1
KIRSCH ARTHUR S
Non-Executive Director
62,535 +48.6%
278.21
US$1,869,261 		62,535 +48.6% 278.21 US$1,869,261
2026-06-24 2026-06-22 PlS Planned sale
Drew Janice Suzann

Chief of Dev. Operations

Officer
46,072 +31.1%
373.64
US$4,467,497 		46,072 +31.1% 373.64 US$4,467,497
2026-06-24 2026-06-22 PlS Planned sale
Pena Luis C.

President & CEO

Executive Director
7,438 -1.2%
22.71
US$168,917 		7,438 -1.2% 22.71 US$168,917
2026-06-24 2026-06-22 PlS Planned sale
Patel Jeegar Pravinkumar

Chief Scientific Officer

Officer
1,488 -3.1%
22.50
US$33,480 		1,488 -3.1% 22.50 US$33,480
2026-06-22 2026-06-22 PrS Proposed sale
JANICE DREW

Officer

Officer
20,000
21.36
US$427,200 		20,000 21.36 US$427,200
2026-06-22 2026-06-22 PrS Proposed sale
JANICE DREW

Officer

Officer
20,000
21.36
US$427,200 		20,000 21.36 US$427,200
2026-06-03 2026-06-02 PlS Planned sale
Cohen David E
Non-Executive Director
600 -3.3%
21.38
US$12,828 		600 -3.3% 21.38 US$12,828
2026-06-03 2026-06-02 PlS Planned sale
Cohen David E
Non-Executive Director
5,456 -23.1%
20.21
US$110,266 		5,456 -23.1% 20.21 US$110,266
2026-06-02 2026-06-02 PrS Proposed sale
DAVID COHEN

Director

Non-Executive Director
9,258
22.17
US$205,250 		9,258 22.17 US$205,250
2026-06-03 2026-06-01 PlS Planned sale
Patel Jeegar Pravinkumar

Chief Scientific Officer

Officer
16,687 -26.4%
22.74
US$379,462 		16,687 -26.4% 22.74 US$379,462
2026-06-03 2026-06-01 PlS Planned sale
Pena Luis C.

President & CEO

Executive Director
16,787 -2.6%
22.74
US$381,736 		16,787 -2.6% 22.74 US$381,736
2026-06-01 2026-06-01 PrS Proposed sale
LUIS PENA

Director; Officer

Executive Director
24,225
23.23
US$562,747 		24,225 23.23 US$562,747
2026-06-01 2026-06-01 PrS Proposed sale
JEEGAR PATEL

Officer

Officer
18,175
23.23
US$422,205 		18,175 23.23 US$422,205
2026-06-01 2026-05-28 PlS Planned sale
Moss Gregory S.

Chief Business & Legal Officer

Officer
14,223 -18.9%
22.83
US$324,711 		14,223 -18.9% 22.83 US$324,711
2026-06-01 2026-05-28 PlS Planned sale
Carver Kyle

Chief Financial Officer

Officer
18,175 -23.4%
22.84
US$415,117 		18,175 -23.4% 22.84 US$415,117
2026-05-28 2026-05-28 PrS Proposed sale
KYLE CARVER

Officer

Officer
25,675
23.34
US$599,254 		25,675 23.34 US$599,254
2026-05-28 2026-05-28 PrS Proposed sale
GREGORY MOSS

Officer

Officer
14,223
23.34
US$331,965 		14,223 23.34 US$331,965
2025-12-22 2025-12-19 B Purchase
2.5
Hopfner Robert Lorne
Non-Executive Director Large shareholder
1,000 +33.0%
17.35
US$17,350 		1,000 +33.0% 17.35 US$17,350
2025-11-12 2025-11-07 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
92,904 +13.4%
16.00
US$1,486,464 		92,904 +13.4% 16.00 US$1,486,464
2025-11-12 2025-11-07 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,157,096 +76.3%
16.00
US$18,513,536 		1,157,096 +76.3% 16.00 US$18,513,536
2025-11-12 2025-11-07 B Purchase
LSP 7 Cooperative UA
Large shareholder
1,562,500 +46.4%
16.00
US$25,000,000 		1,562,500 +46.4% 16.00 US$25,000,000
2025-11-12 2025-11-07 B Purchase
Verduyn-van Weegen Felice Isabel
Non-Executive Director Large shareholder
1,562,500 +46.4%
16.00
US$25,000,000 		1,562,500 +46.4% 16.00 US$25,000,000
Explore more

More insider trading research around Evommune Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America